Annexon, Inc. (ANNX) stock
Close on Nov 11, 2026Market cap $856.62MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $856.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.00
- Dividend yield
- 0.00%
- Free cash flow yield
- -22.13%
Fundamentals
- Net income
- -$198.96M
- EPS, diluted
- -$1.04
- Free cash flow
- -$189.55M
- Book value per share
- $0.70
- Diluted shares
- 205M
Trading
- Next earnings
- Mar 29, 2027 (estimated, during market hours)
- Previous close
- $4.21
- Open
- $4.25
- Day's range
- $4.14 – $4.28
- Volume
- 3,080,149
- Average volume (20 days)
- 3,803,813
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.33
- 52-week range
- $2.54 – $7.18
- RSI (14 days)
- 54.1
- Volatility (1 year)
- 75.0%
- Relative volume
- 0.92×
- WACC
- 11.2%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANNX | S&P 500 | Difference | ANNX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.2% | -2.4% | +6.6 pts | ||
| 3 months | -21.5% | -1.2% | −20.4 pts | ||
| Year to date | -16.5% | +12.3% | −28.8 pts | ||
| 1 year | +41.1% | +12.4% | +28.6 pts | ||
| 3 years | +97.2% | +78.8% | +18.4 pts | +25.4% | +21.4% |
| 5 years | -74.0% | +75.2% | −149.1 pts | -23.6% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Annexon filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- News
- News
About Annexon
Pharmaceutical Preparations
Annexon, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted immunotherapies for complement-mediated neuroinflammatory disorders. The company focuses on inhibiting C1q, the initiating molecule of the classical complement cascade, to treat conditions across three primary therapeutic areas: autoimmune disorders, neurodegeneration, and ophthalmology. Its product candidates include tanruprubart for Guillain-Barré syndrome, vonaprument for geographic atrophy, and ANX1502, an oral small molecule being studied for cold agglutinin disease. Annexon also evaluates therapeutic candidates for Huntington’s disease, amyotrophic lateral sclerosis, and lupus nephritis. Its treatments are designed for patients affected by severe neuroinflammatory diseases.
Company profile, executives and historyAnnexon stock: common questions
What is Annexon's stock price?
ANNX closed at $4.19 on Nov 11, 2026, down 0.48% on the day. Over the past 52 weeks it traded between $2.54 and $7.18.
What is Annexon's market cap?
Annexon was worth $856.62M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ANNX's P/E ratio?
Annexon lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.04), so it has no meaningful P/E ratio.
Does Annexon pay a dividend?
No. Annexon has not paid a cash dividend over the last twelve months.
When does Annexon report earnings next?
Annexon is expected to report Q4 FY2026 results on Mar 29, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ANNX stock performed over the past year?
Including dividends, ANNX returned +41.1% over the past year, against +12.4% for the S&P 500.
How many ANNX shares are sold short?
29M shares were sold short at the latest FINRA report, 15.04% of the float, or 7.2 days of average trading volume.
Who are Annexon's competitors?
Companies most similar to Annexon by business, industry and size include DNTH, ANVS, ZBIO, CLYM, VERA.
See a number that looks wrong?